{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T18:51:56Z","timestamp":1778611916857,"version":"3.51.4"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,7,18]],"date-time":"2006-07-18T00:00:00Z","timestamp":1153180800000},"content-version":"vor","delay-in-days":4155,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[1995,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The molecular basis of the Philadelphia chromosome (Ph) is a structurally altered c\u2010<jats:italic>abl<\/jats:italic> (<jats:italic>bcr\u2010abl<\/jats:italic>) gene which encodes an abnormally large protein with protein tyrosine kinase activity. Herbimycin A, which effectively reduced intracellular phosphorylation by bcr\u2010abl tyrosine kinase, preferentially inhibited the growth of Ph\u2010positive leukemia cell lines. Injection of Ph\u2010positive and \u2010negative leukemia cell lines into mice with severe combined immunodeficiency (SCID) resulted in the death of all mice due to leukemia, although the severity of illness varied according to the cell lines used. Administration of herbimycin A significantly enhanced the survival of mice inoculated with the Ph'\u2010positive leukemia cell lines tested but barely affected the survival of mice inoculated with the Ph\u2010negative leukemia cell lines tested. These results suggest that herbimycin A and related compounds may be useful for the treatment of Ph\u2010positive leukemia. The disease that developed using the Ph\u2010positive leukemia cell line NALM\u201020 resembled human Ph\u2010positive acute lymphoid leukemia. There was an inverse relationship between the survival time of mice and the number of cells inoculated. The SCID mouse\u2010NALM\u201020 human leukemia chimera would be a good experimental model for screening tyrosine kinase inhibitors as therapeutic agents against Ph\u2010positive leukemia.<\/jats:p>","DOI":"10.1002\/ijc.2910600519","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T00:38:53Z","timestamp":1171931933000},"page":"685-688","source":"Crossref","is-referenced-by-count":16,"title":["Treatment of Philadelphia\u2010chromosome\u2010positive human leukemia in scid mouse model with herbimycin A, bcr\u2010abl tyrosine kinase activity inhibitor"],"prefix":"10.1002","volume":"60","author":[{"given":"Yoshio","family":"Honma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhide","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Omura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,18]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"827","article-title":"The severe combined immunodeficient (SCID) mouse as a model for human myeloid leukemias","volume":"7","author":"Cesano A.","year":"1992","journal-title":"Oncogene"},{"key":"e_1_2_1_3_1","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood.V77.11.2463.2463","article-title":"Homing and progression patterns of childhood acute lymphoblastic leukemia in severe combined immunodeficiency mice","volume":"77","author":"Cesano A.","year":"1991","journal-title":"Blood."},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(85)90044-X"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2406902"},{"key":"e_1_2_1_6_1","first-page":"991","article-title":"Growth of primary human acute leukemia in severe combined immunodeficient mice","volume":"19","author":"De Lord C.","year":"1991","journal-title":"Exp. Hematol."},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1990.tb08212.x"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1977.107"},{"key":"e_1_2_1_9_1","first-page":"22255","article-title":"Thiasolidine\u2010diones","volume":"265","author":"Geissler J. F.","year":"1990","journal-title":"J. biol. Chem."},{"key":"e_1_2_1_10_1","first-page":"153","volume-title":"Current perspectives on molecular and cellular oncoloy","author":"Honma Y.","year":"1992"},{"key":"e_1_2_1_11_1","first-page":"189","article-title":"Effects of herbimycin A derivatives on growth and differentiation of K5o2 human leukemic cells","volume":"12","author":"Honma Y.","year":"1992","journal-title":"Anticancer Res."},{"key":"e_1_2_1_12_1","first-page":"331","article-title":"Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity","volume":"49","author":"Honma Y.","year":"1989","journal-title":"Cancer Res."},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1990.tb02524.x"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2595371"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.17.6649"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.6.14.1426765"},{"key":"e_1_2_1_17_1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/jnci\/56.3.627","article-title":"Human myelogenous (Ph+) leukemia cell line: transplantation into athymic mice","volume":"56","author":"Lozzio B. B.","year":"1976","journal-title":"J. nat. Cancer Inst."},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2971269"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/335256a0"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910190309"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.32.255"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(94)90118-X"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.41.831"},{"key":"e_1_2_1_24_1","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1182\/blood.V78.10.2650.2650","article-title":"Growth of primary T\u2010cell non\u2010Hodgkin's lymphoma in SCID\u2010hu mice: requirement for a human lymphoid mieroenvironment","volume":"78","author":"Waller E. K.","year":"1991","journal-title":"Blood."},{"key":"e_1_2_1_25_1","first-page":"2588","article-title":"Transplanlability of human lymphoid cell line, lymphoma, and leukemia in splenectomized and\/or irradiated nude mice","volume":"40","author":"Watanabe S.","year":"1980","journal-title":"Cancer Res."}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.2910600519","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.2910600519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T17:56:39Z","timestamp":1698256599000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.2910600519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,3,3]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1995,3,3]]}},"alternative-id":["10.1002\/ijc.2910600519"],"URL":"https:\/\/doi.org\/10.1002\/ijc.2910600519","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,3,3]]}}}